Physician profile

Adam Eric Perlmutter

Urology · Plymouth, IN

NPI 1235270067

$4,463.45

in general payments reported to CMS, 2019-2025

46 companies · $1,324 in 2025

The $1,324 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,261.68
Education$204.85

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $694.08 2019-2025 Xtandi, Myrbetriq
Janssen Biotech, INC. $364.53 2019-2025 Erleada, Akeega
Sumitomo Pharma America, INC. $323.80 2023-2025 Orgovyx
Pfizer INC. $296.27 2019-2025
Urogen Pharma, INC. $258.36 2021-2025
Endo Pharmaceuticals INC. $224.14 2019-2023 Xiaflex, Aveed
Verity Pharmaceuticals INC. $178.21 2022-2025 Trelstar, Tlando
Abbvie INC. $170.96 2019-2025
Intuitive Surgical, INC. $152.50 2025
Tolmar, INC. $150.58 2023-2024
180 Medical, INC. $136.15 2024-2025 Cure Catheter
Novo Nordisk INC $125.00 2025 Ozempic
Janssen Pharmaceuticals, INC $113.72 2021
Olympus America INC. $111.00 2020-2025 Itind System, Soltive
Boston Scientific Corporation $104.87 2019-2022
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Axonics, INC. $95.82 2020-2022
Laborie Medical Technologies Corp. $85.80 2023-2025 Optilume Bph Drug Coated Balloon Catheter
Astrazeneca Pharmaceuticals LP $80.06 2020-2022
Myriad Genetic Laboratories, INC. $69.77 2021-2024 Prolaris
Myovant Sciences INC. $69.54 2021-2022
Bayer Healthcare Pharmaceuticals INC. $63.38 2019-2025
Coloplast Corp $61.79 2023-2025 Porges Coloplast
Teleflex LLC $51.56 2019-2022
Cardinal Health 414 LLC $31.23 2023
Zyla Life Sciences, INC. $29.64 2020
Dendreon Pharmaceuticals LLC $28.47 2020
Hollister Incorporated $27.83 2021
Progenics Pharmaceuticals, INC. $24.04 2024
Ferring Pharmaceuticals INC. $24.00 2025 Adstiladrin
Endo USA, INC. $23.87 2024 Aveed, Xiaflex
Travere Therapeutics, INC. $23.69 2019
Accord Healthcare, INC. $23.54 2024
Kerecis Limited $23.02 2024 Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose
Profound Medical Corp. $22.97 2025 Tulsa-Pro
Lantheus Medical Imaging, INC. $21.70 2024
Dornier Medtech America, INC $20.83 2019
Coopersurgical, INC. $20.36 2019
Novartis Pharmaceuticals Corporation $19.33 2025
Amgen INC. $17.62 2019
Blue Earth Diagnostics $16.87 2021
Civco Medical Instruments $15.69 2025
Antares Pharma, INC. $15.44 2021
Exact Sciences Corporation $13.90 2025 Cologuard Collection Kit
Clarus Therapeutics INC. $13.06 2021
Merck Sharp & Dohme LLC $12.30 2020
Tolmar Pharmaceuticals, INC. $12.16 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Adam Eric Perlmutter

$4,463.45

in general payments reported 2019-2025

Years
2019-2025
Top company
Astellas Pharma US INC
Context
The $1,324 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

https://glasscript.com/doctor/328423/adam-eric-perlmutter

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.